CHICAGO – A week after he talked with BioWorld Today about his success in helping pharmaceutical firms backfill their dwindling pipelines with promising, early stage deals, Avalon Ventures partner Jay Lichter disclosed a multi-company arrangement designed to do just that in a big way for GlaxoSmithKline plc.